Prognostic impact of intraoperative blood loss in liver transplant patients with advanced hepatocellular carcinoma

Anticancer Research

Volumn 36, Issue 10, 2016, Pages 5355-5364

  Kornberg, Arno ^a   Witt, Ulrike ^a   Kornberg, Jennifer ^b   Ceyhan, Güralp O ^a   Mueller, Katharina ^c   Friess, Helmut ^a   Thrum, Katharina ^d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d HELIOS Hospital Berlin   (Germany)

Author keywords

18F FDG positron emission tomography; Hepatocellular carcinoma; Intraoperative blood loss; Liver transplantation; Milan criteria; Survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; CARCINOMA, HEPATOCELLULAR; INTRAOPERATIVE PERIOD; LIVER NEOPLASMS; PROGNOSIS;

BLOOD LOSS, SURGICAL; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INTRAOPERATIVE PERIOD; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84991834376     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11109     Document Type: Article

References (46)

1. Tabrizian P, Jibara G, Shrager B, Schwartz M and Roayaie S: Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261: 947-955, 2015.
2. Franssen B, Jibara G, Tabrizian P, Schwartz ME and Roayaie S: Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB 16: 830-835, 2014.
3. Kornberg A: Liver transplantation for hepatocellular carcinoma beyond Milan Criteria: Multidisciplinary approach to improve outcome. ISRN Hepatology doi.org/10.1155/2014/706945, 2014.
4. Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR and Busuttil RW: A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg 220: 416-427, 2015.
5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A and Gennari L: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699, 1996.
6. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R and Mariani L: Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 17(Suppl 2): 44-57, 2011.
7. Herrero JI, Sangro B, Pardo F, Quiroga J, Iñarrairaegui M, Rotellar F, Montiel C, Alegre F, and Prieto J: Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl 3: 272-278, 2002.
8. Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G and Vitale A: Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 22: 232-252, 2016.
9. Menon KV, Hakeem AR and Heaton ND: Review article: liver transplantation for hepatocellular carcinoma-a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 60: 1165-1171, 2004.
10. Machado A, Kiss G, Ernani L, Marroni C, Zanotelli ML, Cantisani G, Cerski CT, Coral G and Brandão A: Liver Transplantation Group. Validation of the Metroticket model in a cohort of patients transplanted for hepatocellular carcinoma in southern Brazil. Clin Transplant 29: 806-812, 2015.
11. Teng F, Han QC, Ding GS, Ni ZJ, Fu H, Guo WY, Shi XM, Gao XG, Ma J and Fu ZR: Validation of a criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. Sci Rep 5: 1173, doi: 10.1038/srep11733, 2015.
12. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U and Neuhaus P: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33: 1080-1086, 2001.
13. Zhang Y, Shi ZL, Yang X and Yin ZF: Targeting of circulating hepatocellular carcinoma cells to prevent postoperative recurrence and metastasis. World J Gastroenterol 20: 142-147, 2014.
14. Bailly M, Venel Y, Orain I, Salamé E and Ribeiro MJ: 18F-FDG PET in liver transplantation setting of hepatocellular carcinoma: predicting histology? Clin Nucl Med 41: 126-129, 2016.
15. Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D and Settmacher U: 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 9: 592-600, 2009.
16. Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, Yi NJ and Lee KU: The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 11: 1655-1660, 2006.
17. Gu XQ, Zheng WP, Teng DH, Sun JS and Zheng H: Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients. World J Gastroenterol 22: 2749-2759, 2016.
18. Toso C, Mentha G and Majno P: Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 11: 2031-2035, 2011.
19. Orci LA, Berney T, Majno PE, Lacotte S, Oldani G, Morel P, Mentha G and Toso C: Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation. Br J Surg 102: 1250-1257, 2015.
20. Orci LA, Lacotte S, Oldani G, Morel P, Mentha G and Toso C: The role of hepatic ischemia-reperfusion injury and liver parenchymal quality on cancer recurrence. Dig Dis Sci 59: 2058-2068, 2014.
21. Oldani G, Crowe LA, Orci LA, Slits F, Rubbia-Brandt L, de Vito C, Morel P, Mentha G, Berney T, Vallée JP, Lacotte S and Toso C: Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation. J Hepatol 61: 278-285, 2014.
22. Kornberg A, Witt U, Kornberg J, Friess H and Thrum K: Extended ischemia times promote risk of HCC recurrence in liver transplant patients. Dig Dis Sci 60: 2832-2839, 2015.
23. Nastos C, Kalimeris K, Papoutsidakis N, Tasoulis MK, Lykoudis PM, Theodoraki K, Nastou D, Smyrniotis V and Arkadopoulos N: Global consequences of liver ischemia/reperfusion injury. Oxid Med Cell Longev doi: 10.1155/2014/906965, 2014.
24. Zhai Y, Petrowsky H, Hong JC, Busuttil RW and Kupiec-Weglinski JW: Ischemia-reperfusion injury in liver transplantation-from bench to bedside. Nat Rev Gastroenterol Hepatol 10: 79-89, 2013.
25. Yang T, Zhang J, Lu JH, Yang GS, Wu MC and Yu WF: Risk factors influencing postoperative outcomes of major hepatic resection of hepatocellular carcinoma for patients with underlying liver diseases. World J Surg 35: 2073-2082, 2011.
26. Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH and Dematteo RP: Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg 249: 617-623, 2009.
27. Nanashima A, Abo T, Hamasaki K, Wakata K, Tominaga T, Hidaka S, Takeshita H and Nagayasu T: Perioperative Nontumorous Factors Associated with Survival in HCC Patients Who Underwent Hepatectomy. Anticancer Res 31; 4545-4551, 2011.
28. Tilg H, Nordberg J, Vogel W, Luger TA, Herold M, Aulitzky WE, Margreiter R and Huber C: Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantation. Transplantation 54: 142-146, 1992.
29. Kornberg A, Witt U, Kornberg J, Müller K, Friess H and Thrum K: Postoperative peak serum C-reactive protein is a predictor of outcome following liver transplantation for hepatocellular carcinoma. Biomarkers 8: 1-8, 2015.
30. Feltracco P, Brezzi M, Barbieri S, Galligioni H, Milevoj M, Carollo C and Ori C: Blood loss, predictors of bleeding, transfusion practice and strategies of blood cell salvaging during liver transplantation. World J Hepatol 5: 1-15, 2013.
31. Okamura R, Hida K, Hasegawa S, Sakai Y, Hamada M, Yasui M and Hinoi T, Watanabe M; Japan Society of Laparoscopic Colorectal Surgery: Impact of intraoperative blood loss on morbidity and survival after radical surgery for colorectal cancer patients aged 80 years or older. Int J Colorectal Dis 31: 327-334, 2016.
32. Jiang N, Deng JY, Ding XW, Zhang L, Liu HG, Liang YX and Liang H: Effect of complication grade on survival following curative gastrectomy for carcinoma. World J Gastroenterol 20: 8244-8252, 2014.
33. Teng F, Wang GH, Tao YF, Guo WY, Wang ZX, Ding GS, Shi XM and Fu ZR: Criteria-specific long-term survival prediction model for hepatocellular carcinoma patients after liver transplantation. World J Gastroenterol 20: 10900-10907, 2014.
34. Liu B, Teng F, Fu H, Guo WY, Shi XM, Ni ZJ, Gao XG, Ma J, Fu ZR and Ding GS: Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation. BMC Gastroenterol 15: 138, doi: 10.1186/s12876-015-0364-5, 2015.
35. Nagai S, Yoshida A, Facciuto M, Moonka D, Abouljoud MS, Schwartz ME and Florman SS: Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation. Hepatology 61: 895-904, 2015.
36. Croome KP, Wall W, Chandok N, Beck G, Marotta P and Hernandez-Alejandro R: Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts. Liver Transpl 19: 1214-1223, 2015.
37. Angele MK and Faist E: Clinical review: immunodepression in the surgical patient and increased susceptibility to infection. Crit Care 6: 298-305, 2002.
38. Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, Kim H, Choi YR, Hong G, Lee KW and Suh KS: Impact of imunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol 20: 192-203, 2014.
39. Carmeliet P, Dor Y, Herbert J, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D and Keshert E: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-49, 1998.
40. Li T, Zhu Y, Qin CYJ, Yang Z, Fang A, Xu S and Ren W: Expression and prognostic significance of vascular endothelial growth factor receptor 1 in hepatocellular carcinoma. Clin Pathol 65: 808-814, 2012.
41. Yoong KF, McNab G, Hübscher SG and Adams DH: Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumorinfiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol 160: 3978-3988, 1998.
42. Zucker S and Vacirca J: Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 23: 101-117, 2004.
43. Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, Zhou Y, Zhou Y and Zhang Y: Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS One 8: e64261. doi: 10.1371, 2013.
44. Yang T, Lu JH, Lau WY, Zhang TY, Zhang H, Shen YN, Alshebeeb K, Wu MC, Schwartz M and Shen F: Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis. J Hepatol 64: 583-593, 2016.
45. Kwon AH, Matsui Y and Kamiyama Y: Perioperative blood transfusion in hepatocellular carcinomas: influence of immunologic profile and recurrence free survival. Cancer 91: 771-778, 2001.
46. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.